Asenapine: A Review in Schizophrenia

CNS Drugs
Greg L Plosker, Emma D Deeks

Abstract

Asenapine (Saphris(®), Sycrest(®)) is an atypical antipsychotic that is administered sublingually twice daily and is approved for schizophrenia in the USA, Japan and other countries, but not in the EU. This article reviews the pharmacology, clinical efficacy and tolerability profile of asenapine in the treatment of adults with schizophrenia. Clinical trials with asenapine have demonstrated efficacy in terms of both positive and negative symptoms of schizophrenia, although findings have not always been consistent. Across three short-term (6-week) studies in acute schizophrenia (including one in Asian patients), asenapine was generally superior to placebo and had broadly similar efficacy to active controls in improving total scores on the Positive and Negative Syndrome Scale. A meta-analysis of four short-term trials with asenapine (that also included a negative study and a failed trial) also showed significant benefit with asenapine over placebo. In longer-term trials and extensions (up to ≈3 years' duration), asenapine was effective relative to placebo in preventing relapse in schizophrenia, but was less effective than olanzapine in patients with schizophrenia or schizoaffective disorder (according to intent-to-treat LOCF analy...Continue Reading

Citations

Jan 6, 2001·Neuron·D A Lewis, J A Lieberman
Dec 31, 2002·Psychoneuroendocrinology·R Tandon, M D Jibson
May 27, 2005·PLoS Medicine·Sukanta SahaJohn McGrath
Jun 1, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Wulf RösslerAnita Riecher-Rössler
Oct 13, 2006·Psychiatric Services : a Journal of the American Psychiatric Association·Brian J MillerDale P Svendsen
Aug 28, 2007·The Psychiatric Clinics of North America·Erick L MessiasWilliam W Eaton
Oct 27, 2007·The Journal of Clinical Psychiatry·Steven G PotkinJohn Panagides
Aug 23, 2008·Journal of Psychopharmacology·Frank I TaraziMohammed Shahid
May 23, 2009·Psychopharmacology·Hugh MarstonMohammed Shahid
Jun 2, 2011·Journal of Clinical Pharmacology·Mireille G F GerritsPierre Peeters
Jun 10, 2011·Clinical Pharmacokinetics·Pierre PeetersRik de Greef
Jul 15, 2011·International Journal of Geriatric Psychiatry·Steven L DubovskyJohn Panagides
Dec 27, 2011·Journal of Clinical Psychopharmacology·Robert W BuchananPilar Cazorla
Nov 6, 2012·Expert Opinion on Drug Discovery·Frank I Tarazi, Jo C Neill
Mar 29, 2013·Journal of Psychopharmacology·Leonardo CorteseSergey N Mosolov
Feb 7, 2014·The Journal of Clinical Psychiatry·David E KempArmin Szegedi
May 6, 2014·Expert Opinion on Drug Metabolism & Toxicology·Leslie Citrome
Jul 1, 2014·Expert Opinion on Drug Safety·Felix-Martin Werner, Rafael Coveñas
Nov 5, 2014·Clinical Schizophrenia & Related Psychoses·David J Castle, Jens-Kristian Slott Jensen
Feb 7, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Chris A OosterhofPierre Blier
Jun 3, 2015·Current Drug Metabolism·Roberto MandrioliLaura Mercolini
Apr 22, 2016·Acta Neuropsychiatrica·Masayo OhyamaTsukasa Koyama

Related Concepts

Study
Antipsychotic Effect
Atypical Antipsychotic [EPC]
Meta-Analysis (Publications)
Meta Analysis (Statistical Procedure)
Schizoaffective Disorder
Oral Hypoesthesia
Olanzapine
Acute Schizophrenia
Hypesthesia

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here